NPT 200 11
Alternative Names: NPT200-11; UCB-1332Latest Information Update: 28 Oct 2019
At a glance
- Originator Neuropore Therapies
- Developer Neuropore Therapies; UCB
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple system atrophy; Parkinson's disease
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Multiple system atrophy in USA (PO)
- 28 Sep 2018 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO)
- 20 Sep 2016 Phase-I clinical trials in Multiple system atrophy in USA (PO) before September 2016 (Neuropore pipeline, September 2016)